Drug or technology
21 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 8, 2026 · JOURNAL ARTICLE
Innovative Medicines & Omics
This is a mechanistic review proposing a novel conceptual framework linking PAH chronotoxicity to cancer via circadian dysregulation; it raises questions rather than testing them empirically.
SEP 8, 2026 · JOURNAL ARTICLE
Biomedicines
This is a narrative review synthesizing mechanistic concepts and therapeutic rationales without reporting primary empirical findings, clinical trial data, or comparative evidence from original research.
SEP 8, 2026 · JOURNAL ARTICLE
Theoretical and Natural Science
A narrative review of mechanistic pathways linking protein lactylation to cancer phenotypes; raises questions about therapeutic potential but reports no empirical data, effect sizes, or clinical outcomes.
AUG 19, 2026 · JOURNAL ARTICLE
Molecules and Cells
Mechanistic proof-of-concept in cell lines using CRISPR-dCas9 epigenetic editing, without in vivo validation or clinical outcomes, raising a therapeutic hypothesis rather than establishing efficacy.
AUG 18, 2026 · JOURNAL ARTICLE
Peerj
This is a narrative review synthesizing mechanistic observations about SHMT2 in cancer; it raises questions about therapeutic potential rather than testing an intervention or reporting new empirical evidence.
AUG 17, 2026 · JOURNAL ARTICLE
Seminars in Immunology
This is a narrative review that synthesizes existing knowledge about cellular senescence mechanisms in liver disease; it raises questions about therapeutic targeting rather than reporting original empirical results or clinical outcomes.
AUG 17, 2026 · JOURNAL ARTICLE
Scientific Reports
In vitro mechanistic study in cancer cell lines demonstrating that DNMT1 inhibition modulates EMT markers and reduces invasiveness in docetaxel-resistant prostate cancer, but lacks in vivo validation, clinical endpoints, or human data.
AUG 15, 2026 · JOURNAL ARTICLE
BMC Cancer
Systematic review of 20 studies confirming that tissue-based DNA methylation is frequently associated with worse survival in NSCLC, but methodological heterogeneity and lack of meta-analysis prevent definitive clinical recommendations.